Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    Subscribe
    Home»HealthCare»Diagens Launches DoctorBench, Setting a New Global Benchmark for ‘Real-World Clinical Performance’ in Medical Foundation Models
    HealthCare

    Diagens Launches DoctorBench, Setting a New Global Benchmark for ‘Real-World Clinical Performance’ in Medical Foundation Models

    Marie JonesBy Marie JonesApril 30, 2026Updated:May 1, 2026No Comments3 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    HONG KONG, Apr 30, 2026 – (ACN Newswire) – Hangzhou Diagens Biotechnology Co., Ltd. (2526.HK, “Diagens”) today officially launched DoctorBench, a medical AI evaluation platform, and unveiled its inaugural global medical foundation model leaderboard in Hong Kong. WiseDiag Technology’s WiseDiag-v2, Google’s Gemini-3.1-Pro-Preview, and OpenAI’s GPT-5.4 secured the top three positions.

    For the first time, the evaluation framework places “real-world clinical performance” at the center, constructing a multi-dimensional benchmarking system that closely mirrors authentic diagnostic and treatment scenarios.

    As medical foundation models accelerate their transition from laboratory research to clinical application worldwide, the industry has long lacked a metric that genuinely measures a model’s “clinical competence.” Existing evaluations predominantly focus on medical knowledge recall, failing to capture a model’s comprehensive performance in complex clinical contexts. This gap between benchmarking and clinical reality has become a global obstacle hindering the deployment of medical AI.

    OpenAI previously launched HealthBench, signaling that leading players are beginning to take this challenge seriously. However, medicine is inherently localized — diagnostic and treatment guidelines, language conventions, and patient populations vary significantly across countries and regions, rendering any single evaluation system insufficient for universal applicability.

    Driven by a profound understanding of this global challenge, Diagens developed the DoctorBench platform. The platform’s creation is rooted in nearly a decade of deep collaboration by a cross-disciplinary team. Diagens brought together experts in basic medicine, clinical medicine, artificial intelligence, and the healthcare industry, tightly integrating rigorous clinical logic with cutting-edge deep learning algorithms. This enables DoctorBench to both comprehend the boundaries of AI technology and grasp the intricate demands of clinical practice, using that standard to construct its evaluation framework.

    The core philosophy of DoctorBench is no longer to test a model’s “knowledge base,” but to assess its clinical communication and decision-making ability — its capacity to “think like a doctor.” The platform features three leaderboard tracks: the Medical Leaderboard (LLM), the Multimodal Leaderboard (VLM), and the Agent Leaderboard — evaluating textual diagnostic ability, multimodal understanding, and multi-turn decision-making with tool-use inside a simulated clinical environment respectively.

    On the evaluation mechanism, DoctorBench pioneers a multi-dimensional architecture combining “2 Core Dimensions (Safety and Accuracy) + 3 General Dimensions (Interaction Quality, Information Prioritization, Proactive Inquiry) + 5 Specialized Modules (Evidence & Citation, Explainable Reasoning, Actionability, Personalized Adaptation, Emotional Support).” It is equipped with “Scenario-Adaptive Weighting,” dynamically adjusting the weight of each dimension according to the risk level of different clinical scenarios, making the scoring logic closely aligned with real-world diagnostic decision-making.

    Crucially, the platform designates “Medical Factual Accuracy” and “Safety and Risk Control” as inviolable red lines with a “one-vote veto” power. Any model that exhibits critical deviations on issues affecting patient safety will be unable to achieve a high score, regardless of outstanding performance in other dimensions. This design stems from the team’s deep understanding of the essence of medicine: in a field where lives are at stake, safety is always the paramount principle and leaves no room for compromise.

    “The advancement of medical AI is a long-distance race concerning the health and well-being of all humanity. It demands not only disruptive technological innovation and deep cross-disciplinary, cross-regional collaboration, but also an absolute reverence for and unwavering commitment to life and health,” said Dr. Song Ning, Founder of Diagens. He expressed the hope of joining hands with more global research institutions, clinical centers, and industry partners, so that truly capable technologies can be recognized, trusted, and ultimately used to benefit every patient.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleFosun Subsidiaries Post Solid Q1, Core Businesses Fuel Growth
    Next Article Wintermar Offshore (WINS:JK) Reports 1Q2026 Results

    Related Posts

    CanSinoBIO Reports Growth in First Nine Months: Commercialization Accelerates Across Multiple Products as Platform Innovation Opens New Avenues for Growth

    October 27, 2026

    Hengrui Pharma Reports Steady Growth in the First Nine Months of 2026

    October 27, 2026

    Micot Pharma Showcases First-in-Class, Brain-Penetrant TrkB Agonist MT200605 at World Stroke Congress, Building the Case for Global Partnerships and Commercialization

    October 27, 2026
    Add A Comment
    Leave A Reply Cancel Reply

    Latest News

    • Garuda Indonesia Advances Digital Transformation, Expands Travel Flexibility with Upgraded Manage My Booking Service
    • Chervon Launches Advanced Momentum Program (AMP) to Hire & Develop the Next Generation of Leaders
    • Autumn Lighting Fair, Outdoor and Tech Light Expo, Eco Expo Asia draw some 62,000 buyers
    • OMRON Healthcare Begins Full-Scale Production at First Factory in India
    • Rasa Light Je: Spritzer Sparkling Invites Malaysians to Go Light on Themselves with a Positive Approach to Everyday Wellbeing
    • Garuda Indonesia Group’s Transformation Programme Drives 13.2% Revenue Growth to US$2.71 Billion Amid High Jet Fuel Prices
    • CIMC Group Announces Results for the First Three Quarters of 2026
    • TANAKA MIRAI Lab., JAF MEDIA WORKS, and Della Begin Joint Research to Visualize Drivers’ Conditions through Analysis of Sweat Components
    • U.S. Polo Assn. Executes Early on Europe’s Digital Product Passport Mandate
    • COSCO SHIPPING Ports Announces 2026 Third Quarter Results
    © 2026 BusinessNewsAsia.com

    Type above and press Enter to search. Press Esc to cancel.